0001193125-24-144951.txt : 20240522 0001193125-24-144951.hdr.sgml : 20240522 20240522161012 ACCESSION NUMBER: 0001193125-24-144951 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240516 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240522 DATE AS OF CHANGE: 20240522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 24973314 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d807494d8k.htm 8-K 8-K
NASDAQ false 0000863894 0000863894 2024-05-16 2024-05-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2024

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 4.01

Changes in Registrant’s Certifying Accountant

 

(a)

Dismissal of Independent Registered Public Accounting Firm

On May 16, 2024, Veru Inc. (the “Company”) dismissed RSM US LLP (“RSM”) as its independent registered public accounting firm. The decision to dismiss RSM was approved by the Company’s Audit Committee. As described below, the change in independent registered public accounting firm is not the result of any disagreement with RSM.

The reports of RSM on the Company’s financial statements for the fiscal years ended September 30, 2023 and 2022, did not contain an adverse opinion or a disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the report for the fiscal year ended September 30, 2023 included an explanatory paragraph indicating that there was substantial doubt about the Company’s ability to continue as a going concern.

During the Company’s fiscal years ended September 30, 2023 and 2022, and in the subsequent interim period through May 16, 2024, (i) there were no “disagreements” as that term is defined in Item 304(a)(1)(iv) of Regulation S-K promulgated by the Securities and Exchange Commission (“SEC”) pursuant to the Securities Exchange Act of 1934, between the Company and RSM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of RSM, would have caused RSM to make reference to the subject matter of the disagreement in connection with its reports on the financial statements for such years, and (ii) there were no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K, except for (A) the material weakness in the Company’s internal control over financial reporting disclosed in Part I, Item 4 of the Company’s Form 10-Q/A for the quarter ended June 30, 2023 filed with the SEC on November 15, 2023, which resulted in a restatement of the Company’s previously issued unaudited condensed consolidated financial statements as of and for the three and nine months ended June 30, 2023, as a material weakness in the Company’s internal control over financial reporting was identified related to its controls over applying technical accounting guidance to nonrecurring events and transactions, specific to the evaluation of information that was known or knowable at the time of the transaction or event, and (B) the material weakness in the Company’s internal control over financial reporting disclosed in Part II, Item 9A of the Company’s Form 10-K/A for the year ended September 30, 2023 filed with the SEC on April 1, 2024, which resulted in a restatement of the Company’s previously issued consolidated financial statements as of and for the years ended September 30, 2023 and 2022, as a material weakness in the Company’s internal control over financial reporting was identified related to its management review control over its estimate of research and development expenses associated with activities conducted by third-party service providers. RSM provided written communication to the Audit Committee regarding the material weaknesses and the subject matter of the material weaknesses was discussed by the Company’s management and the Audit Committee with RSM. The Audit Committee discussed the restatements of the Company’s financial statements with RSM. The Company has authorized RSM to respond fully to the inquiries of the successor accountant concerning the subject matter of each such “reportable event.”

The Company has provided RSM with a copy of the foregoing disclosures and has requested that RSM review such disclosures and provide a letter addressed to the SEC as specified by Item 304(a)(3) of Regulation S-K. A copy of RSM’s letter to the SEC is attached to this report as Exhibit 16.1.

 

(b)

Appointment of New Independent Registered Public Accounting Firm

On May 21, 2024, following approval by the Audit Committee, the Company engaged Cherry Bekaert LLP as its new independent registered public accounting firm to succeed RSM.

The Company has not consulted with Cherry Bekaert LLP during the Company’s fiscal years ended September 30, 2023 and 2022, and in the subsequent interim period through May 21, 2024, regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that Cherry Bekaert LLP concluded was an important factor considered by the Company in reaching a decision as to an accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K) or a “reportable event” (as described in Item 304(a)(1)(v) of Regulation S-K).

 

2


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

  

Document

16.1    Letter of RSM US LLP dated May 22, 2024 concerning change in the registrant’s certifying accountant.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 22, 2024     VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
     

Chief Financial Officer and

Chief Administrative Officer

 

4

EX-16.1 2 d807494dex161.htm EX-16.1 EX-16.1

Exhibit 16.1

 

LOGO

May 22, 2024

Securities and Exchange Commission

Washington, D.C. 20549

Commissioners:

We have read Veru Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on May 22, 2024 and we agree with such statements concerning our firm.

 

LOGO

 

LOGO

RSM US LLP is the U.S. member firm of RSM International, a global network of independent audit, tax, and consulting firms. Visit rsmus.com/aboutus for more information regarding RSM US LLP and RSM International.

EX-101.SCH 3 veru-20240516.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 veru-20240516_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 veru-20240516_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g807494dsp05a.jpg GRAPHIC begin 644 g807494dsp05a.jpg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end GRAPHIC 7 g807494dsp05b.jpg GRAPHIC begin 644 g807494dsp05b.jpg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end GRAPHIC 8 g807494dsp05d.jpg GRAPHIC begin 644 g807494dsp05d.jpg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�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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 16, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000863894
Document Type 8-K
Document Period End Date May 16, 2024
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address, Address Line One 2916 N. Miami Avenue
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33127
City Area Code (305)
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - d807494d8k.htm 7 d807494d8k.htm veru-20240516.xsd veru-20240516_lab.xml veru-20240516_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d807494d8k.htm": { "nsprefix": "veru", "nsuri": "http://verupharma.com/20240516", "dts": { "inline": { "local": [ "d807494d8k.htm" ] }, "schema": { "local": [ "veru-20240516.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "veru-20240516_lab.xml" ] }, "presentationLink": { "local": [ "veru-20240516_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-16_to_2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d807494d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-16_to_2024-05-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d807494d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://verupharma.com//20240516/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 19 0001193125-24-144951-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-144951-xbrl.zip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end XML 21 d807494d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2024-05-16 2024-05-16 NASDAQ false 0000863894 8-K 2024-05-16 VERU INC. WI 1-13602 39-1144397 2916 N. Miami Avenue Suite 1000 Miami FL 33127 (305) 509-6897 false false false false Common Stock, $0.01 par value per share VERU false